BIOTECH MARKET RESEARCH $XLO | Ep. 557

Xilo Therapeutics

Mark your calendars—Xilo Therapeutics' XTX-101 vilastobart and atezolizumab combo data in colorectal cancer (CRC) is almost here. With the market abuzz and options pricing signaling an implied volatility of +/- 150%, all eyes are on this combo aiming to transform outcomes for patients with refractory CRC. Stay tuned—this readout could mark a turning point for Xilo and bring new hope to an underserved patient population!

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: XTX-101 vilastobart and atezolizumab combo data in colorectal cancer (CRC)

DATE: Jan 23-25 at ASCO GI

IMPLIED VOLATILITY: +/- 150%

BACKGROUND: